权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Targeting the Core Binding Factor tumor suppressor in MLL-fusion AML

靶向 MLL 融合 AML 中的核心结合因子肿瘤抑制因子

基本信息

批准号：
8645095
负责人：
HARTMUT GEIGER
金额：
$ 22.46万
依托单位：
P2D, INC.
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-08-01 至 2016-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8645095
关键词：
11q23 AML1-ETO fusion protein Accounting Acute Myelocytic Leukemia Animals Attention Biological Models Blood Cells Cancer Cell Growth Cell Proliferation Cell Survival Cell model Cells Chemotherapy-Oncologic Procedure Chimeric Proteins Chromosomal translocation Clinic Combined Modality Therapy Core-Binding Factor Cytarabine DNA Damage Data Development Disease Disease remission Dominant-Negative Mutation Doxorubicin Dysmyelopoietic Syndromes Ectopic Expression Effectiveness Event Fluorescence Resonance Energy Transfer Fusion Protein Expression Gene Mutation Genetic Models Growth Hematologic Neoplasms Human Human Development Immunodeficient Mouse In Vitro Lesion Leukemic Cell MLL-AF9 MYH11 gene Measures Mediating Modeling Molecular Mus Mutation Myeloproliferative disease Nuclear Patients Phase Point Mutation Proteins RUNX1 gene Recurrence Relapse Role Sampling Signal Transduction Small Business Innovation Research Grant Testing Therapeutic Therapeutic Effect Toxicity Tests Translating Transplantation Treatment outcome Tumor Suppressor Proteins Umbilical Cord Blood Work Xenograft Model base cancer therapy cell growth chemotherapy clinical application commercialization human cord blood CD34+ cell in vivo in vivo Model inhibitor/antagonist innovative technologies leukemia mutant novel phase 2 study pre-clinical preclinical study public health relevance small hairpin RNA small molecule t(8 21)(q22 q22)therapeutic target

项目摘要

DESCRIPTION (provided by applicant): RUNX1 is considered a beneficial tumor suppressor in myeloid neoplasms. Inhibition of RUNX1 function has been implicated as an important mechanistic event in the development of core-binding factor-(CBF)-leukemia and MLL-fusion leukemia. Inactivating RUNX1 mutations are frequently found in patients with acute myeloid leukemia (AML). However, RUNX1 mutation is usually heterozygous, complete loss of RUNX1 in AML is rare and no somatic RUNX1 mutation have been found in AMLs with common fusion proteins, such as CBF- and MLL-fusion leukemias. These data raise the possibility that a certain (low) level of RUNX1 activity is required for survival and growth of AML. We have developed human models for AML by transducing leukemogenic fusion proteins into human cord blood CD34+ cells. MLL-AF9-expressing cord blood cells cause human leukemia when transplanted into immunodeficient mice. We recently found that these AML cells critically depend on RUNX1 activity for sustained growth and survival, indicating that RUNX1 is a promising therapeutic strategy for AML. We will clarify molecular mechanisms underlying RUNX1-mediated survival/growth of AML cells and translate these findings into the clinic, using a novel RUNX1 inhibitor in murine xenograft models of human AML. This study will provide a proof of principle to the proposed strategy, and will serve as useful preclinical preliminary data for clinical application.

描述（由申请人提供）：RUNX 1被认为是骨髓肿瘤中的有益肿瘤抑制因子。RUNX 1功能的抑制被认为是核心结合因子（CBF）白血病和MLL融合白血病发展中的重要机制事件。失活RUNX 1突变经常在急性髓性白血病（AML）患者中发现。然而，RUNX 1突变通常是杂合的，在AML中RUNX 1的完全丢失是罕见的，并且在具有常见融合蛋白的AML中未发现体细胞RUNX 1突变，例如CBF融合白血病和MLL融合白血病。这些数据提高了AML生存和生长需要一定（低）水平RUNX 1活性的可能性。我们通过将致白血病融合蛋白转导入人脐带血CD 34+细胞，开发了AML的人类模型。MLL-AF 9表达的脐带血细胞在移植到免疫缺陷小鼠中时引起人类白血病。我们最近发现，这些AML细胞严重依赖于RUNX 1活性来维持生长和存活，这表明RUNX 1是AML的一种有前途的治疗策略。我们将阐明RUNX 1介导的AML细胞存活/生长的分子机制，并将这些发现转化为临床，在人类AML的小鼠异种移植模型中使用新型RUNX 1抑制剂。本研究将为所提出的策略提供原理证明，并将为临床应用提供有用的临床前初步数据。